Completed PHASE1 INTERVENTIONAL 3-arm NCT00966602

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Cystic Fibrosis

Interventions Placebo VX-770 VX-809 VX-809 & VX-770

Updated 6 times since 2017 Last updated: Jan 2, 2010 Started: Sep 30, 2009 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00966602, this PHASE1 trial focuses on Cystic Fibrosis and remains completed. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zuidlaren, Netherlands